GSK Is First Big Pharma To Seek Gene Therapy Approval, Plans More
This article was originally published in The Pink Sheet Daily
Executive Summary
Britain’s biggest drug maker is seeking regulatory approval in Europe to use gene transfer technology in children born with ADA-SCID and has further programs using the approach in two other rare diseases - metachromatic leukodystrophy and Wiskott-Aldrich syndrome - with both currently in clinical trials.
You may also be interested in...
Merck KGaA Bags Exclusive Rights To Develop, Sell Debiopharm’s Xevinapant
Germany’s Merck has licensed exclusive rights to develop and sell Debiopharm’s potential first-in-class inhibitor of apoptosis proteins (IAP) antagonist, targeting head and neck cancers.
Patient-Centric: Evotec’s CSO Explains R&D Strategy
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk, Evotec Link Around Chronic Kidney Disease
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: